Hee Won Cho

Hee Won Cho

Auto-generated profile, based on publicly available information

Hee Won Cho

Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
HCHee Won Cho
Hee Won Cho
JLJi Won Lee
Ji Won Lee
YMYoungeun Ma
Youngeun Ma
KYKeon Hee Yoo
Keon Hee Yoo
KSKi Woong Sung
Ki Woong Sung
HKHong Hoe Koo
Hong Hoe Koo
Cho HW, et al. J Korean Med Sci. 2018 Sep;33(41):e260. https://doi.org/10.3346/jkms.2018.33.e260

1 March 2021 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
RCRihwa Choi
Rihwa Choi
MCMi Ryung Chun
Mi Ryung Chun
JPJisook Park
Jisook Park
JLJi Won Lee
Ji Won Lee
HJHee Young Ju
Hee Young Ju
PHPh.D.
Ph.D.
Rihwa Choi, M.D., Mi Ryung Chun, M.S., Jisook Park, Ph.D., Ji Won Lee, M.D., Ph.D., Hee Young Ju, M.D., Hee Won Cho, M.D., Ju Kyung Hyun, M.D., Hong Hoe Koo, M.D., Ph.D., Eun Sang Yi, M.D., and Soo-Youn Lee, M.D., Ph.D.. Ann Lab Med 2021;41:145-54. https://doi.org/10.3343/alm.2021.41.2.145

30 June 2020 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
JLJi Won Lee
Ji Won Lee
DLDo Hoon Lim
Do Hoon Lim
KSKi Woong Sung
Ki Woong Sung
HCHee Won Cho
Hee Won Cho
HJHee Young Ju
Hee Young Ju
HSHyung Jin Shin
Hyung Jin Shin
Background: In this study, we report the follow‐up results of reduced dose of craniospinal radiotherapy (CSRT) followed by tandem high‐dose chemotherapy (HDCT) in patients with high‐risk medulloblastoma (MB).Methods: Newly diagnosed high‐risk MB patients (metastatic disease, postoperative residual tumor >1.5 cm2, or large cell/anaplastic histology) over 3 years of age were enrolled in this study. Two cycles of pre‐RT chemotherapy, radiotherapy (RT) including reduced‐dose CSRT (23.4 or 30.6 Gy), four cycles of post‐RT chemotherapy, and tandem HDCT were administered. NanoString and DNA sequencing were performed using archival tissues.Results: In all, 40 patients were enrolled, and molecular subgrouping was possible in 21 patients (2 wingless, 3 sonic hedgehog, 8 Group 3, and 8 group 4). All patients including two patients who experienced progression during the induction chemotherapy underwent HDCT. Relapse/progression occurred only in four patients (5‐year cumulative incidence [CI] 10.4 ± 0.3%). However, six patients died from treatment‐related mortality (TRM) (four acute TRMs and two late TRMs) resulting in 18.5 ± 0.5% of 5‐year CI. Taken together, the 5‐year event‐free survival and overall survival were 71.1 ± 8.0% and 73.2 ± 7.9%, respectively. Late effects were evaluated in 25 patients and high‐tone hearing loss, endocrine dysfunction, dyslipidemia, and growth retardation were common.Conclusions: The strategy using tandem HDCT following reduced‐dose CSRT showed promising results in terms of low relapse/progression rate; however, the high TRM rate indicates that modification of HDCT regimen and careful selection of patients who can benefit from HDCT will be needed in the future study.

1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
HLHana Lim
Hana Lim
MSMeong Hi Son
Meong Hi Son
JHJu Kyung Hyun
Ju Kyung Hyun
HCHee Won Cho
Hee Won Cho
HJHee Young Ju
Hee Young Ju
HKHong Hoe Koo
Hong Hoe Koo
Lim H, et al. J Korean Med Sci. 2020 Feb;35(14):e82. https://doi.org/10.3346/jkms.2020.35.e82

1 January 2023 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JLJi Won Lee
Ji Won Lee
YYYohwan Yeo
Yohwan Yeo
HJHee Young Ju
Hee Young Ju
HCHee Won Cho
Hee Won Cho
KYKeon Hee Yoo
Keon Hee Yoo
YSYun-Mi Song
Yun-Mi Song
Lee JW, et al. J Korean Med Sci. 2023 Jul;38(29):e230. https://doi.org/10.3346/jkms.2023.38.e230

7 February 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YPYong-Jin Park
Yong-Jin Park
JLJi Won Lee
Ji Won Lee
HCHee Won Cho
Hee Won Cho
YCYearn Seong Choe
Yearn Seong Choe
KLKyung-Han Lee
Kyung-Han Lee
SMSeung Hwan Moon
Seung Hwan Moon
Purpose: The purpose of this study was to investigate the value of C-11 methionine (MET) positron emission tomography (PET)/computed tomography (CT) in patients with intracranial germinoma (IG). Material and methods: We conducted a retrospective analysis of 21 consecutive patients with pathologically confirmed IGs and eight patients with intracranial non-germinomas (INGs) located in a similar region. Clinical characteristics, imaging findings, and tumor markers such as α-fetoprotein (AFP) and β-human chorionic gonadotropin (HCG) were used as clinical variables. Maximum standardized uptake value (SUVmax), tumor-to-normal tissue (T/N) ratio, and visual scoring of tumor were used as MET PET parameters. Results: All IGs were well visualized on MET PET with a three-grade visual scoring system. In addition, SUVmax of IGs was higher than that of INGs (P = 0.005). Pre-treatment (Pre-Tx) T/N ratio was significantly correlated with pre-Tx serum HCG (P = 0.031). Moreover, MET PET parameters showed significant associations with tumor location, sex, KRAS variant, and symptoms. Conclusion: MET PET/CT could be a useful diagnostic tool in patients suspected of having IGs. In addition, the MET avidity of tumor is a potential surrogate biomarker of HCG, which has been used as a diagnostic marker for IGs. Tumor MET parameters also had significant differences according to tumor locations, sex, symptoms, and KRAS mutation. However, MET avidity of tumors had no significant prognostic value.